# Luxia Zhang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/luxia-zhang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,112 |
| Field | Chronic Kidney Disease and Diabetes |
| h-index | 58 |
| i10-index | 183 |
| Last Known Institution | Peking University |
| OpenAlex ID | https://openalex.org/A5063338849 |
| ORCID iD | 0000-0003-2349-2936 |
| Works | 340 |

## Researcher papers

Showing 12 of 15.

- [KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease](https://scholariq.org/papers/kdigo-2024-clinical-practice-guideline-for-the-evaluation-and-management-of/)
- [Prevalence of chronic kidney disease in China: a cross-sectional survey](https://scholariq.org/papers/prevalence-of-chronic-kidney-disease-in-china-a-cross-sectional-survey/)
- [Prevalence and Disease Burden of Chronic Kidney Disease](https://scholariq.org/papers/prevalence-and-disease-burden-of-chronic-kidney-disease/)
- [The path to healthy ageing in China: a Peking University–Lancet Commission](https://scholariq.org/papers/the-path-to-healthy-ageing-in-china-a-peking-university-lancet-commission/)
- [Trends in Chronic Kidney Disease in China](https://scholariq.org/papers/trends-in-chronic-kidney-disease-in-china/)
- [Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study](https://scholariq.org/papers/chronic-kidney-disease-and-cardiovascular-risk-in-six-regions-of-the-world-isn/)
- [Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency](https://scholariq.org/papers/change-in-albuminuria-and-gfr-as-end-points-for-clinical-trials-in-early-stages/)
- [Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis](https://scholariq.org/papers/associations-of-kidney-disease-measures-with-mortality-and-end-stage-renal-2/)
- [Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns](https://scholariq.org/papers/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-3/)
- [Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes](https://scholariq.org/papers/estimated-glomerular-filtration-rate-albuminuria-and-adverse-outcomes/)
- [Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis](https://scholariq.org/papers/serum-potassium-and-adverse-outcomes-across-the-range-of-kidney-function-a-ckd/)
- [Prevalence and Factors Associated With CKD: A Population Study From Beijing](https://scholariq.org/papers/prevalence-and-factors-associated-with-ckd-a-population-study-from-beijing/)

## Researcher topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Healthcare Systems and Reforms](https://scholariq.org/topics/healthcare-systems-and-reforms/)
- [Climate Change and Health Impacts](https://scholariq.org/topics/climate-change-and-health-impacts/)

## Researcher university

- [Peking University](https://scholariq.org/institutions/peking-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.